Ironwood Pharma (I76) Stock Statistics & Valuation Metrics
Total Valuation
Ironwood Pharma has a market cap or net worth of EUR 517.10M. The enterprise value is EUR 1.02B.
- Market Cap
- EUR 517.10M
- Enterprise Value
- EUR 1.02B
Share Statistics
Ironwood Pharma has 165,239,940 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 165,239,940
- Owned by Insiders
- 3.82%
- Owned by Institutions
- 37.32%
Financial Efficiency
Ironwood Pharma’s return on equity (ROE) is -0.09 and return on invested capital (ROIC) is 11.39%.
- Return on Equity (ROE)
- -0.09
- Return on Assets (ROA)
- 0.06
- Return on Invested Capital (ROIC)
- 11.39%
- Return on Capital Employed (ROCE)
- 0.77
- Revenue Per Employee
- 2.96M
- Profits Per Employee
- 240.17K
- Employee Count
- 100
- Asset Turnover
- 0.75
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Ironwood Pharma is 4.35. Ironwood Pharma’s PEG ratio is 0.00.
- PE Ratio
- 4.35
- PS Ratio
- 1.47
- PB Ratio
- -3.54
- Price to FCF
- 3.08
- Price to Operating Cash Flow
- 3.09
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Ironwood Pharma had revenue of 296.15M and earned 24.02M in profits. Earnings per share was 0.15.
- Revenue
- 296.15M
- Gross Profit
- 296.15M
- Operating Income
- 118.76M
- Pretax Income
- 70.03M
- Net Income
- 24.02M
- EBITDA
- 104.65M
- Earnings Per Share (EPS)
- 0.15
Cash Flow
In the last 12 months, operating cash flow was 185.56M and capital expenditures -1,000, giving a free cash flow of 185.55M billion.
- Operating Cash Flow
- 185.56M
- Free Cash Flow
- 185.55M
- Free Cash Flow per Share
- 1.12
Dividends & Yields
Ironwood Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 32.50%
- Earnings Yield
- 22.72%
Stock Price Statistics
- Beta
- 0.95
- 52-Week Price Change
- 134.11%
- 50-Day Moving Average
- 3.35
- 200-Day Moving Average
- 3.30
- Relative Strength Index (RSI)
- 41.22
- Average Volume (3m)
- 3,048
Important Dates
Ironwood Pharma upcoming earnings date is Nov 05, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
Ironwood Pharma as a current ratio of 1.13, with Debt / Equity ratio of -228.31%
- Current Ratio
- 1.13
- Quick Ratio
- 1.13
- Debt to Market Cap
- 1.07
- Net Debt to EBITDA
- 3.65
- Interest Coverage Ratio
- 3.63
Taxes
In the past 12 months, Ironwood Pharma has paid 46.01M in taxes.
- Income Tax
- 46.01M
- Effective Tax Rate
- 0.66
Enterprise Valuation
Ironwood Pharma EV to EBITDA ratio is 3.67, with an EV/FCF ratio of 4.79.
- EV to Sales
- 2.28
- EV to EBITDA
- 3.67
- EV to Free Cash Flow
- 4.79
- EV to Operating Cash Flow
- 4.79
Balance Sheet
Ironwood Pharma has EUR 79.13M in cash and marketable securities with EUR 396.87M in debt, giving a net cash position of -EUR 317.74M billion.
- Cash & Marketable Securities
- EUR 79.13M
- Total Debt
- EUR 396.87M
- Net Cash
- -EUR 317.74M
- Net Cash Per Share
- -EUR 1.92
- Tangible Book Value Per Share
- -EUR 0.99
Margins
Gross margin is 99.76%, with operating margin of 60.64%, and net profit margin of 33.36%.
- Gross Margin
- 99.76%
- Operating Margin
- 60.64%
- Pretax Margin
- 53.27%
- Net Profit Margin
- 33.36%
- EBITDA Margin
- 62.13%
- EBIT Margin
- 61.66%
Analyst Forecast
The average price target for Ironwood Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 18.10%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 7
- AI Score
- ―
